부산대학교 도서관

Shah, Bijal D ; Ghobadi, Armin ; Oluwole, Olalekan O ; Logan, Aaron C ; Boissel, Nicolas ; Cassaday, Ryan D ; Leguay, Thibaut ; Bishop, Michael R ; Topp, Max S ; Tzachanis, Dimitrios ; O'Dwyer, Kristen M ; Arellano, Martha L ; Lin, Yi ; Baer, Maria R ; Schiller, Gary J ; Park, Jae H ; Subklewe, Marion ; Abedi, Mehrdad ; Minnema, Monique C ; Wierda, William G ; DeAngelo, Daniel J ; Stiff, Patrick ; Jeyakumar, Deepa ; Feng, Chaoling ; Dong, Jinghui ; Shen, Tong ; Milletti, Francesca ; Rossi, John M ; Vezan, Remus ; Masouleh, Behzad Kharabi ; Houot, Roch

In The Lancet 7-13 August 2021 398(10299):491-502

Zeidner JF; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States.; Jain J; The Ohio State University, Columbus, Ohio, United States.; Welkie RL; The Ohio State University, Columbus, Ohio, United States.; Huang Y; The Ohio State University, Columbus, Ohio, United States.; Swords R; OHSU Knight Cancer Institute Center for Hematologic Malignancies, Portland, Oregon, United States.; Traer E; Oregon Health & Science University, Portland, Oregon, United States.; Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, United States.; Lin TL; University of Kansas, Fairway, Kansas, United States.; Madanat YF; UT Southwestern Medical Center, Dallas, Texas, United States.; Collins RH Jr; UT Southwestern Medical Center, Dallas, Texas, United States.; Baer MR; University of Maryland, Baltimore, Maryland, United States.; Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States.; Blum W; Emory University, Atlanta, Georgia, United States.; Arellano ML; Winship Cancer Institute of Emory University, Atlanta, Georgia, United States.; Stock WA; University of Chicago, Chicago, Illinois, United States.; Odenike O; University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois, United States.; Olin RL; University of California San Francisco, San Francisco, California, United States.; Smith CC; University of California (San Francisco), San Francisco, California, United States.; Foran JM; Mayo Clinic Florida, Jacksonville, Florida, United States.; Schiller GJ; David Geffen School of Medicine at UCLA, Los Angeles, California, United States.; Curran E; University of Cincinnati College of Medicine, Cincinnati, Ohio, United States.; Handa S; The Ohio State University, Columbus, Ohio, United States.; Heerema NA; The Ohio State University, Columbus, Ohio, United States.; Chen TL; The Ohio State University, Columbus, Ohio, United States.; Martycz M; The Ohio State University Wexner Medical Center, Delaware, Ohio, United States.; Stefanos M; OSU, Columbus, Ohio, United States.; Marcus S; The Leukemia and Lymphoma Society, Rye Brook, New York, United States.; Rosenberg L; The Leukemia and Lymphoma Society, Rye Brook, New York, United States.; Druker BJ; Oregon Health & Science University, Portland, Oregon, United States.; Levine RL; Memorial Sloan-Kettering Cancer Center, New York, New York, United States.; Burd A; The Leukemia and Lymphoma Society, Rye Brook, New York, United States.; Yocum AO; Blood Cancer United, Washington, District of Columbia, United States.; Mims AS; The Ohio State University, Columbus, Ohio, United States.; Byrd JC; The University of Cincinnati, Cincinnati, Ohio, United States.; Borate UM; The Ohio State University, Columbus, Ohio, United States.

Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

DiNardo, Courtney D ; Foran, James M ; Watts, Justin M ; Stein, Eytan M ; de Botton, Stéphane ; Fathi, Amir T ; Prince, Gabrielle T ; Stein, Anthony S ; Stone, Richard M ; Patel, Prapti A ; Roboz, Gail J ; Arellano, Martha L ; Erba, Harry P ; Pigneux, Arnaud ; Stuart, Robert K ; Thomas, Xavier ; Uy, Geoffrey L ; Lemieux, Ian R ; Zhang, Vickie ; Kapsalis, Stephanie M ; Garcia-Manero, Guillermo ; Sallman, David A

In Clinical Lymphoma, Myeloma and Leukemia September 2021 21 Supplement 1:S346-S347

DiNardo, Courtney D ; Foran, James M ; Watts, Justin M ; Stein, Eytan M ; De Botton, Stéphane ; Fathi, Amir T ; Prince, Gabrielle T ; Stein, Anthony S ; Stone, Richard M ; Patel, Prapti A ; Roboz, Gail J ; Arellano, Martha L ; Erba, Harry P ; Pigneux, Arnaud ; Stuart, Robert K ; Thomas, Xavier ; Uy, Geoffrey L ; Lemieux, Ian R ; Zhang, Vickie ; Kapsalis, Stephanie M ; Garcia-Manero, Guillermo ; Sallman, David A

In Clinical Lymphoma, Myeloma and Leukemia September 2021 21 Supplement 1:S230-S230

Pullarkat V; Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. vpullarkat@coh.org.; Pratz KW; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.; Recher C; Centre Hospitalier Universitaire de Toulouse, Toulouse, France.; Thirman MJ; Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA.; DiNardo CD; Montefiore-Einstein Comprehensive Cancer Center, Bronx, NY, USA.; Fenaux P; Hôpital St. Louis/Assistance Publique-Hôpitaux de Paris and Université de Paris, Paris, France.; Schuh AC; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Wei AH; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Melbourne, VIC, Australia.; Pigneux A; Department of Hematology, CHU de Bordeaux, Bordeaux, France.; Jang JH; Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.; Juliusson G; Department of Hematology, Skåne University Hospital, Lund, Sweden.; Miyazaki Y; Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.; Selleslag D; Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium.; Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.; Liu C; AbbVie Inc., North Chicago, IL, USA.; Ridgeway JA; AbbVie Inc., North Chicago, IL, USA.; Potluri J; AbbVie Inc., North Chicago, IL, USA.; Schuler J; AbbVie Inc., North Chicago, IL, USA.; Konopleva M; Montefiore-Einstein Comprehensive Cancer Center, Bronx, NY, USA.

Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process

Hoff FW; University of Texas Southwestern Medical Center, Dallas, TX.; Huang Y; The Ohio State University, Columbus, OH.; Welkie RL; The Ohio State University, Columbus, OH.; Swords RT; Knight Cancer Institute, Oregon Health and Science University, Portland, OR.; Traer E; Knight Cancer Institute, Oregon Health and Science University, Portland, OR.; Stein EM; Memorial Sloan Kettering Cancer Center, New York, NY.; Lin TL; University of Kansas Medical Center, Kansas City, KS.; Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.; Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.; Blum WG; Winship Cancer Institute of Emory University, Atlanta, GA.; Arellano ML; Winship Cancer Institute of Emory University, Atlanta, GA.; Stock W; University of Chicago, Chicago, IL.; Odenike O; University of Chicago, Chicago, IL.; Zeidner JF; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.; Olin RL; University of California, San Francisco, San Francisco, CA.; Smith CC; University of California, San Francisco, San Francisco, CA.; Schiller GJ; David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.; Curran EK; University of Cincinnati, Cincinnati, OH.; Handa SV; The Ohio State University, Columbus, OH.; Heerema NA; The Ohio State University, Columbus, OH.; Chen T; The Ohio State University, Columbus, OH.; Martycz M; The Ohio State University, Columbus, OH.; Stefanos M; The Ohio State University, Columbus, OH.; Marcus SG; Blood Cancer United, Washington, DC.; Rosenberg L; Blood Cancer United, Washington, DC.; Druker BJ; Knight Cancer Institute, Oregon Health and Science University, Portland, OR.; Levine RL; Memorial Sloan Kettering Cancer Center, New York, NY.; Burd A; Blood Cancer United, Washington, DC.; Yocum AO; Blood Cancer United, Washington, DC.; Borate UM; The Ohio State University, Columbus, OH.; Mims AS; The Ohio State University, Columbus, OH.; Byrd JC; University of Cincinnati, Cincinnati, OH.; Madanat YF; University of Texas Southwestern Medical Center, Dallas, TX. yazan.madanat@utsouthwestern.edu.

Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

DiNardo, Courtney D ; Foran, James M ; Watts, Justin M ; Stein, Eytan M ; Botton, Stéphane de ; Fathi, Amir T ; Prince, Gabrielle T ; Stein, Anthony S ; Stone, Richard M ; Patel, Prapti A ; Roboz, Gail J ; Arellano, Martha L ; Erba, Harry P ; Pigneux, Arnaud ; Stuart, Robert K ; Thomas, Xavier ; Uy, Geoffrey L ; Oluyadi, Abdulafeez ; Lemieux, Ian R ; Liu, Hua ; Wu, Bin ; Winkler, Thomas ; Garcia-Manero, Guillermo ; Sallman, David A

In Clinical Lymphoma, Myeloma and Leukemia September 2020 20 Supplement 1:S321-S321

Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA.; Thirman MJ; Department of Medicine, Section of Hematology and Oncology, The University of Chicago Medicine, Chicago, IL.; DiPersio JF; Department of Medicine, Washington University School of Medicine, St Louis, MO.; Heiblig M; Hematology Department, Centre Hospitalier Lyon Sud, Lyon, France.; Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Schuh AC; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.; Žučenka A; Faculty of Medicine, Hematology and Oncology Department, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.; de Botton S; Hematologie Clinique, Institut Gustave Roussy, Villejuif, France.; Grove CS; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.; Department of Haematology, PathWest Inc, Nedlands, WA, Australia.; Department of Haematology, University of Western Australia, Nedlands, WA, Australia.; Mannis GN; Division of Hematology, Stanford University School of Medicine, Stanford, CA.; Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy.; Perl AE; Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA.; Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Aldoss I; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.; Bajel A; Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.; Department of Haematology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.; Dickens DS; Division of Pediatric Hematology/Oncology, University of Iowa Stead Family Children's Hospital, Iowa City, IA.; Kühn MWM; Department of Hematology and Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.; Mantzaris I; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.; Raffoux E; Adult Hematology Department, Hospital Saint Louis, Université Paris Diderot, Paris, France.; Traer E; Division of Hematology/Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR.; Amitai I; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.; School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.; Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.; Greco C; Division of Hematology, Ospedale San Bortolo, Aulss Berica, Vicenza, Italy.; Kovacsovics T; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Phoenix, Goodyear, AZ.; McMahon CM; Department of Hematology, University of Colorado School of Medicine, Aurora, CO.; Montesinos P; Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.; Pigneux A; Hematology Department, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.; Shami PJ; Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.; Stone RM; Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA.; Wolach O; School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Harpel JG; ICON plc, New York, NY.; Chudnovsky Y; Syndax Pharmaceuticals, Inc, Waltham, MA.; Yu L; Syndax Pharmaceuticals, Inc, Waltham, MA.; Bagley RG; Syndax Pharmaceuticals, Inc, Waltham, MA.; Smith AR; Syndax Pharmaceuticals, Inc, Waltham, MA.; Blachly JS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Shah BD; Moffitt Cancer Center, Tampa, FL, USA. bijal.shah@moffitt.org.; Cassaday RD; University of Washington & Fred Hutchinson Cancer Center, Seattle, WA, USA.; Park JH; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Houot R; CHU Rennes, Univ Rennes, Inserm & EFS, Rennes, France.; Logan AC; UCSF Medical Center, San Francisco, CA, USA.; Boissel N; Hôpital Saint-Louis, Paris, France.; Leguay T; Service d'hématologie clinique et thérapie cellulaire Hopital du Haut-Lévêque CHU de Bordeaux, Bordeaux, France.; Bishop MR; The University of Chicago Medicine, Chicago, IL, USA.; Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.; O'Dwyer KM; University of Rochester Medical Center, Rochester, NY, USA.; Tzachanis D; University of California San Diego, San Diego, CA, USA.; Arellano ML; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Lin Y; Mayo Clinic, Rochester, MN, USA.; Baer MR; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Schiller GJ; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Subklewe M; Ludwig-Maximilians-Universität München, München, Germany.; Abedi M; University of California Davis Comprehensive Cancer Center Sacramento, Davis, CA, USA.; Minnema MC; UMC Utrecht Cancer Center, MS Hematologie, University Medical Center Utrecht, on behalf of HOVON/LLPC, Utrecht, Netherlands.; Wierda WG; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA.; Stiff P; Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.; Jeyakumar D; University of California Irvine Medical Center, Orange, CA, USA.; Mao D; Kite, a Gilead Company, Santa Monica, CA, USA.; Adhikary S; Kite, a Gilead Company, Santa Monica, CA, USA.; Zhou L; Kite, a Gilead Company, Santa Monica, CA, USA.; Hadjivassileva T; Kite, a Gilead Company, Santa Monica, CA, USA.; Damico Khalid R; Kite, a Gilead Company, Santa Monica, CA, USA.; Ghobadi A; Washington University School of Medicine, St Louis, MO, USA.; Oluwole OO; Vanderbilt University Cancer Center, Nashville, TN, USA.

Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Huang Y; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Welkie RL; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Swords RT; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Traer E; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Stein EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Lin TL; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.; Patel PA; Servier Pharmaceuticals, LLC, Boston, MA, USA.; Collins RH Jr; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Baer MR; Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Duong VH; Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Stock W; Department of Medicine, University of Chicago, Chicago, IL, USA.; Odenike O; Department of Medicine, University of Chicago, Chicago, IL, USA.; Redner RL; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Kovacsovics T; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT, USA.; Deininger MW; Department of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI, USA.; Zeidner JF; Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.; Olin RL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Smith CC; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Foran JM; Department of Internal, Medicine Mayo Clinic, Jacksonville, FL, USA.; Schiller GJ; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.; Curran EK; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.; Koenig KL; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Heerema NA; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Chen T; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Martycz M; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Stefanos M; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Marcus SG; Leukemia and Lymphoma Society, Rye Brook, NY, USA.; Rosenberg L; Leukemia and Lymphoma Society, Rye Brook, NY, USA.; Druker BJ; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Burd A; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.; Yocum AO; Leukemia and Lymphoma Society, Rye Brook, NY, USA.; Borate UM; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Mims AS; Department of Medicine, The Ohio State University, Columbus, OH, USA.; Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.; Madanat YF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. yazan.madanat@utsouthwestern.edu.

Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process

Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.; Ruppert AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Mims AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Borate U; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.; Stock W; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.; Kovacsovics T; Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah, USA.; Blum W; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.; Arellano ML; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.; Schiller GJ; David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.; Olin RL; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA.; Foran JM; Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.; Litzow MR; Departments of Medical Oncology, Hematology, and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Patel PA; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA.; Foster MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Redner RL; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.; Al-Mansour Z; Department of Medicine, University of Florida, Gainesville, Florida, USA.; Cogle CR; Department of Medicine, University of Florida, Gainesville, Florida, USA.; Swords RT; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Collins RH; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA.; Vergilio JA; Foundation Medicine, Cambridge, Massachusetts, USA.; Heerema NA; Department of Pathology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Rosenberg L; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.; Yocum AO; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.; Marcus S; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.; Chen T; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Druggan F; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Stefanos M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Gana TJ; Biopharmatech Consulting, Inc., Leesburg, Virginia, USA.; Shoben AB; Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, USA.; Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.; Burd A; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.; Byrd JC; Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.; Levine RL; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Boyiadzis MM; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Roddie C; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Sandhu KS; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Tholouli E; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Logan AC; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Shaughnessy P; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Barba P; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Ghobadi A; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Guerreiro M; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Yallop D; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Abedi M; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Pantin JM; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Yared JA; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Beitinjaneh AM; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Chaganti S; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Hodby K; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Menne T; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Arellano ML; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Malladi R; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Shah BD; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Mountjoy L; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; O'Dwyer KM; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Peggs KS; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Lao-Sirieix P; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Zhang Y; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Brugger W; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Braendle E; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Pule M; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Bishop MR; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; DeAngelo DJ; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Park JH; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).; Jabbour E; From the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King's College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) - all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) - all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) - both in Texas; Hospital Universitari Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) - both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) - both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) - both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana-Farber Cancer Institute, Boston (D.J.D.).

Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.; Huang Y; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Welkie RL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Swords RT; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Traer E; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Stein EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Lin TL; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS.; Archer KJ; Division of Biostatistics, The Ohio State University, Columbus, OH.; Patel PA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Collins RH; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Baer MR; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD.; Duong VH; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD.; Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.; Stock W; Department of Medicine, The University of Chicago, Chicago, IL.; Odenike O; Department of Medicine, The University of Chicago, Chicago, IL.; Redner RL; Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA.; Kovacsovics T; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT.; Deininger MW; Department of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI.; Zeidner JF; Division of Hematology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.; Olin RL; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Smith CC; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Foran JM; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL.; Schiller GJ; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.; Curran EK; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH.; Koenig KL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH.; Chen T; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Martycz M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Stefanos M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Marcus SG; Leukemia & Lymphoma Society, Rye Brook, NY.; Rosenberg L; Leukemia & Lymphoma Society, Rye Brook, NY.; Druker BJ; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Burd A; Leukemia & Lymphoma Society, Rye Brook, NY.; Yocum AO; Leukemia & Lymphoma Society, Rye Brook, NY.; Borate UM; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Mims AS; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH.; Byrd JC; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH.; Madanat YF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Shah, Bijal D; Ghobadi, Armin; Oluwole, Olalekan O; Logan, Aaron C; Boissel, Nicolas; Cassaday, Ryan D; Leguay, Thibaut; Bishop, Michael R; Topp, Max S; Tzachanis, Dimitrios; O’Dwyer, Kristen M; Arellano, Martha L; Lin, Yi; Baer, Maria R; Schiller, Gary J; Park, Jae H; Subklewe, Marion; Abedi, Mehrdad; Minnema, Monique C; Wierda, William G; DeAngelo, Daniel J; Stiff, Patrick; Jeyakumar, Deepa; Dong, Jinghui; Adhikary, Sabina; Zhou, Lang; Schuberth, Petra C; Faghmous, Imi; Masouleh, Behzad Kharabi; Houot, Roch

J Hematol Oncol
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-11 (2022)
Journal of Hematology & Oncology, vol 15, iss 1

Roddie, Claire; Sandhu, Karamjeet; Tholouli, Eleni; Shaughnessy, Paul; Barba Suñol, Pere; Nuno Direito de Morais Guerreiro, Manuel; Abedi, Mehrdad; Bishop, Michael; Yared, Jean; Ghobadi, Armin; Yallop, Deborah; Logan, Aaron; Amer, Beitinjaneh; Pantin, Jeremy; Arellano, Martha L; Chaganti, Sridhar; Malladi, Ram; Menne, Tobias; Escamilla, Virginia; Hodby, Katharine

HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p

DiNardo CD; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.; Roboz GJ; Clinical and Translational Leukemia Programs, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.; Watts JM; Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.; Madanat YF; Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX.; Prince GT; Division of Hematologic Malignancy, Johns Hopkins Hospital, Baltimore, MD.; Baratam P; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC.; de Botton S; Hematologie Clinique, Institut Gustave Roussy, Villejuif, Faculté Paris-Saclay, Institut Gustave Roussy, Villejuif, France.; Stein A; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.; Foran JM; Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL.; Arellano ML; Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.; Sallman DA; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.; Hossain M; Servier Pharmaceuticals, LLC, Boston, MA.; Marchione DM; Servier Pharmaceuticals, LLC, Boston, MA.; Bai X; Servier Pharmaceuticals, LLC, Boston, MA.; Patel PA; Servier Pharmaceuticals, LLC, Boston, MA.; Kapsalis SM; Servier Pharmaceuticals, LLC, Boston, MA.; Garcia-Manero G; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.; Fathi AT; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Begna KH; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Altman JK; Department of Medicine, Northwestern University, Chicago, Illinois.; Goldberg SL; Hackensack University Medical Center, Hackensack, New Jersey.; Sekeres MA; Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, Ohio.; Strickland SA; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.; Arellano ML; Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia.; Claxton DF; Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.; Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Gautier M; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.; Berman E; Memorial Sloan Kettering Cancer Center, New York, New York.; Seiter K; Department of Medicine, New York Medical College, Valhalla, New York.; Solomon SR; Northside Hospital Cancer Institute, Leukemia Program, Atlanta, Georgia.; Schiller GJ; Hematological Malignancy/Stem Cell Transplant Program, David Geffen School of Medicine at the University of California, Los Angeles, California.; Luger SM; Department of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.; Butrym A; Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.; Gaidano G; Division of Hematology, Maggiore della Carita University Hospital, Novara, Italy.; Thomas XG; Hematology, South Hospital Center, Lyon, France.; Montesinos P; La Fe University and Polytechnic Hospital, Valencia, Spain.; Rizzieri DA; Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Quick DP; Joe Arrington Cancer Center, Lubbock, Texas.; Venugopal P; Department of Medicine, Hematology, and Oncology, Rush University Medical Center, Chicago, Illinois.; Gaur R; St Luke's Cancer Institute, Kansas City, Missouri.; Maness LJ; Division of Hematology-Oncology Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.; Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Buyse ME; International Drug Development Institute, Louvain-la-Neuve, Belgium.; Chiao JH; Cyclacel Limited, Dundee, United Kingdom.

Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Shah, Bijal D; Cassaday, Ryan D; Park, Jae H.; Houot, Roch; Oluwole, Olalekan O; Logan, Aaron C; Boissel, Nicolas; Leguay, Thibaut; Bishop, Michael R; Topp, Max S; Tzachanis, Dimitrios; O’dwyer, Kristen M; Arellano, Martha L; Lin, Yi; Baer, Maria R; Schiller, Gary J; Subklewe, Marion; Abedi, Mehrdad; Minnema, Monique C.; Wierda, William G; Deangelo, Daniel; Stiff, Patrick J; Jeyakumar, Deepa; Mao, Daqin; Adhikary, Sabina; Zhou, Lang; Schuberth, Petra C; Damico Khalid, Rita; Ghobadia, Armin

J Immunother Cancer
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Journal for ImmunoTherapy of Cancer, vol 11, iss 8

Arellano, Martha L; Borthakur, Gautam; Berger, Mark; Luer, Jill; Raza, Azra

Clinical Lymphoma, Myeloma & Leukemia; 2014 Dec, Vol. 14 Issue 6, p534-539, 6p

Saliba AN; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.; Kaufmann SH; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.; Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Patel PA; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.; Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.; Stock W; Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL.; Deininger M; Division of Hematology and Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.; Blum W; Winship Cancer Institute of Emory University, Atlanta, GA.; Schiller GJ; David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.; Olin RL; University of California, San Francisco, San Francisco, CA.; Litzow MR; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.; Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.; Ball BJ; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.; Boyiadzis MM; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.; Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Odenike O; Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL.; Arellano ML; Winship Cancer Institute of Emory University, Atlanta, GA.; Walker A; The Ohio State University, Columbus, OH.; Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.; Kovacsovics T; Division of Hematology and Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.; Collins RH; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.; Shoben AB; The Ohio State University, Columbus, OH.; Heerema NA; The Ohio State University, Columbus, OH.; Foster MC; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.; Peterson KL; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN.; Schneider PA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN.; Martycz M; The Ohio State University, Columbus, OH.; Gana TJ; Biopharmatech Consulting, Inc., Leesburg, VA.; Rosenberg L; Leukemia and Lymphoma Society, White Plains, NY.; Marcus S; Leukemia and Lymphoma Society, White Plains, NY.; Yocum AO; Leukemia and Lymphoma Society, White Plains, NY.; Chen T; The Ohio State University, Columbus, OH.; Stefanos M; The Ohio State University, Columbus, OH.; Mims AS; The Ohio State University, Columbus, OH.; Borate U; The Ohio State University, Columbus, OH.; Burd A; Leukemia and Lymphoma Society, White Plains, NY.; Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Levine RL; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Byrd JC; Department of Medicine, University of Cincinnati, Cincinnati, OH.; Foran JM; Division of Hematology-Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL.

Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE